LEADER 03668nam 22006135 450 001 9910369940703321 005 20200706055535.0 010 $a3-030-31113-9 024 7 $a10.1007/978-3-030-31113-1 035 $a(CKB)4100000009844710 035 $a(DE-He213)978-3-030-31113-1 035 $a(MiAaPQ)EBC5979124 035 $a(PPN)253181410 035 $a(EXLCZ)994100000009844710 100 $a20191114d2020 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAtlas of Response to Immunotherapy /$fedited by Egesta Lopci, Stefano Fanti 205 $a1st ed. 2020. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2020. 215 $a1 online resource (VIII, 127 p. 111 illus., 100 illus. in color.) 311 $a3-030-31112-0 327 $aPART I BRIEF INTRODUCTION: Immunotherapy in oncology -- Evolution of response criteria -- Part II DIESEASE-ORIENTED APPLICATIONS: CNS -- Thorax -- Melanoma -- Gastrointestinal -- Genitourinary -- Hematologic -- Other tumor types -- PART III PITFALLS AND IMMUNE-RELATED ADVERSE EVENTS (IrAEs) PART IV IMMUNO-PET. 330 $aThis atlas is a concise but comprehensive guide to the diverse patterns of response to immunotherapy as observed on Positron Emission Tomography/Computed Tomography (PET/CT) and other conventional imaging modalities, including CT and Magnetic Resonance Imaging (MRI). The purpose for this publication is to fill the gap between the growing clinical relevance and utilization of immunotherapy in medical oncology, mainly based on checkpoint inhibitors, and the need for experienced imagers with reliable tools assessing response to treatment. A series of disease-oriented chapters will present the imaging findings during immunotherapy in the major oncological settings, with helpful comparison of functional (PET/CT) and morphological (CT/MRI) patterns of response in individual cases. To complete the atlas, a dedicated chapter will focus on major pitfalls and immune-related adverse events (irAEs) affecting image interpretation during the course of immunotherapy. The concluding chapter will lastly examine the available data and potential developments of immuno-PET, which is considered as the novel frontier of research in this oncological scenario. The atlas will be of high value for radiologists and nuclear medicine specialists at all levels of experience. 606 $aNuclear medicine 606 $aOncology   606 $aImmunology 606 $aRadiology 606 $aNuclear Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H29048 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 606 $aImmunology$3https://scigraph.springernature.com/ontologies/product-market-codes/B14000 606 $aDiagnostic Radiology$3https://scigraph.springernature.com/ontologies/product-market-codes/H29013 615 0$aNuclear medicine. 615 0$aOncology  . 615 0$aImmunology. 615 0$aRadiology. 615 14$aNuclear Medicine. 615 24$aOncology. 615 24$aImmunology. 615 24$aDiagnostic Radiology. 676 $a616.07548 676 $a616.079 702 $aLopci$b Egesta$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aFanti$b Stefano$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910369940703321 996 $aAtlas of Response to Immunotherapy$92210788 997 $aUNINA